Tumor Biology

, Volume 37, Issue 2, pp 2673–2682 | Cite as

CIP2A is associated with multidrug resistance in cervical adenocarcinoma by a P-glycoprotein pathway

  • Juan Liu
  • Meng Wang
  • Xiaoli Zhang
  • Qingwei Wang
  • Mei Qi
  • Jing Hu
  • Zhiqiang Zhou
  • Chunyan Zhang
  • Weifang Zhang
  • Weiming Zhao
  • Xiao Wang
Original Article


Cancerous inhibitor of protein phosphatase 2A (CIP2A) is a recently identified oncoprotein. Here, we investigated its role in the formation of multidrug resistance (MDR) of cervical adenocarcinoma in vitro and in vivo. MTT assay showed that knockdown of CIP2A expression increased the drug sensitivity of HeLa and Dox-resistant HeLa cells (HeLa-Dox) to doxorubicin, cisplatin, and paclitaxel significantly, while overexpression of CIP2A decreased the sensitivity of HeLa cells to chemo-drugs dramatically. When treated with different chemotherapeutics, CIP2A and P-glycoprotein (P-gp) protein levels were increased in HeLa cells simultaneously. In accordance with it, knockdown or overexpression of CIP2A expression inhibited or increased the P-gp expression in the transcription level separately. The effects of CIP2A on P-gp expression was achieved partly through its regulation on the transcription factor E2F1. Moreover, the interference of CIP2A could decrease the P-gp protein activity elucidated by Rhodamine 123 (Rh123) efflux assay in HeLa and HeLa/Dox cells. In the in vivo level, confocal microscopy data demonstrated the strong co-localization of CIP2A and P-gp protein in HeLa cells, and CIP2A protein expression was significantly associated with that of P-gp in cervical adenocarcinoma tissues. Thus, CIP2A is involved in regulating multidrug resistance of cervical adenocarcinoma upon chemotherapy by enhancing P-gp expression through E2F1. CIP2A may be an attractive target in anticancer strategies to improve the effect of chemotherapy in cervical adenocarcinoma.


Cervical cancer Cancerous inhibitor of protein phosphatase 2A Chemotherapy Multidrug resistance P-glycoprotein 



This research was supported by the National Natural Science Foundation of China (grant no. 81000733), Shandong Province Natural Science Foundation (grant nos. ZR2011HQ036 and ZR2012HM031), and the National Natural Science Foundation of China (grant nos. 81101259 and 81472552).

Conflicts of interest


Supplementary material

13277_2015_4032_MOESM1_ESM.doc (228 kb)
ESM 1 (DOC 228 kb)


  1. 1.
    Yugawa T, Kiyono T. Molecular mechanisms of cervical carcinogenesis by high-risk human papillomaviruses: novel functions of E6 and E7 oncoproteins. Rev Med Virol. 2009;19(2):97–113.CrossRefPubMedGoogle Scholar
  2. 2.
    Sherman ME, Wang SS, Carreon J, Devesa SS. Mortality trends for cervical squamous and adenocarcinoma in the United States. Relation to incidence and survival. Cancer. 2005;103(6):1258–64.CrossRefPubMedGoogle Scholar
  3. 3.
    Fujiwara H et al. Gynecologic Cancer InterGroup (GCIG) consensus review for cervical adenocarcinoma. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S96–101.CrossRefPubMedGoogle Scholar
  4. 4.
    Pectasides D, Kamposioras K, Papaxoinis G, Pectasides E. Chemotherapy for recurrent cervical cancer. Cancer Treat Rev. 2008;34(7):603–13.CrossRefPubMedGoogle Scholar
  5. 5.
    Amin ML. P-glycoprotein inhibition for optimal drug delivery. Drug Target Insights. 2013;19(7):27–34.CrossRefGoogle Scholar
  6. 6.
    Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta. 1976;455:152–62.CrossRefPubMedGoogle Scholar
  7. 7.
    Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem. 1993;62:385–427.CrossRefPubMedGoogle Scholar
  8. 8.
    Zhang H, Zhang X, Wu X, Li W, Su P, Cheng H, et al. Interference of Frizzled 1 (FZD1) reverses multidrug resistance in breast cancer cells through the Wnt/β-catenin pathway. Cancer Lett. 2012;323(1):106–13.CrossRefPubMedGoogle Scholar
  9. 9.
    Lopes-Rodrigues V, Seca H, Sousa D, Sousa E, Lima RT, Vasconcelos MH. The network of P-glycoprotein and microRNAs interactions. Int J Cancer. 2014;135(2):253–63.CrossRefPubMedGoogle Scholar
  10. 10.
    Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol. 1999;39:361–98.CrossRefPubMedGoogle Scholar
  11. 11.
    Junco JJ, Mancha A, Malik G, Wei SJ, Kim DJ, Liang H, et al. Resveratrol and P-glycoprotein inhibitors enhance the anti-skin cancer effects of ursolic acid. Mol Cancer Res. 2013;11(12):1521–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Schneider J, Efferth T, Mattern J, Rodriguez-Escudero FJ, Volm M. Immunohistochemical detection of the multi-drug-resistance marker P-glycoprotein in uterine cervical carcinomas and normal cervical tissue. Am J Obstet Gynecol. 1992;166(3):825–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Junttila MR, Puustinen P, Niemelä M, Ahola R, Arnold H, Böttzauw T, et al. CIP2A inhibits PP2A in human malignancies. Cell. 2007;130(1):51–62.CrossRefPubMedGoogle Scholar
  14. 14.
    Li W, Ge Z, Liu C, Björkholm M, Jia J, Xu D. CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells. Clin Cancer Res. 2008;14(12):3722–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Niemelä M, Kauko O, Sihto H, Mpindi JP, Nicorici D, Pernilä P, et al. CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes. Oncogene. 2012;31(39):4266–78.CrossRefPubMedGoogle Scholar
  16. 16.
    Dong QZ, Wang Y, Dong XJ, Li ZX, Tang ZP, Cui QZ, et al. CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Ann Surg Oncol. 2011;18(3):857–65.CrossRefPubMedGoogle Scholar
  17. 17.
    Vaarala MH, Väisänen MR, Ristimäki A. CIP2A expression is increased in prostate cancer. J Exp Clin Cancer Res. 2010;29:136.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Wang J, Li W, Li L, Yu X, Jia J, Chen C. CIP2A is over-expressed in acute myeloid leukaemia and associated with HL60 cells proliferation and differentiation. Int J Lab Hematol. 2011;33(3):290–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Liu J, Wang X, Zhou G, Wang H, Xiang L, Cheng Y, et al. Cancerous inhibitor of protein phosphatase 2A is overexpressed in cervical cancer and upregulated by human papillomavirus 16 E7 oncoprotein. Gynecol Oncol. 2011;122(2):430–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Côme C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X, et al. CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res. 2009;15(16):5092–100.CrossRefPubMedGoogle Scholar
  21. 21.
    Yu HC, Chen HJ, Chang YL, Liu CY, Shiau CW, Cheng AL, et al. Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma. Biochem Pharmacol. 2013;85(3):356–66.CrossRefPubMedGoogle Scholar
  22. 22.
    Tseng LM, Liu CY, Chang KC, Chu PY, Shiau CW, Chen KF. CIP2A is a target of bortezomib in human triple negative breast cancer cells. Breast Cancer Res. 2012;14(2):R68.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Liu CY, Shiau CW, Kuo HY, Huang HP, Chen MH, Tzeng CH, et al. Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells. Haematologica. 2013;98(5):729–38.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Gao P, Zhou G, Guo L, Zhang QH, Zhen JH, Fang AJ, et al. Reversal of 355 drug resistance in breast carcinoma cells by anti-mdr1 ribozyme regulated by 356 the tumor-specific MUC-1 promoter. Cancer Lett. 2007;256(1):81–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Teodori E, Dei S, Martelli C, Scapecchi S, Gualtieri F. The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR). Curr Drug Targets. 2006;7(7):893–909.CrossRefPubMedGoogle Scholar
  26. 26.
    Ferrandina G, Mantegna G, Petrillo M, Fuoco G, Venditti L, Terzano S, et al. Quality of life and emotional distress in early stage and locally advanced cervical cancer patients: a prospective, longitudinal study. Gynecol Oncol. 2012;124(3):389–94.CrossRefPubMedGoogle Scholar
  27. 27.
    Khanna A, Pimanda JE, Westermarck J. Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target. Cancer Res. 2013;73(22):6548–53.CrossRefPubMedGoogle Scholar
  28. 28.
    Laine A et al. Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1. Cancer Discov. 2013;3(2):182–97.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Yan LH et al. Overexpression of E2F1 in human gastric carcinoma is involved in anti-cancer drug resistance. BMC Cancer. 2014;14:904.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Zhang W et al. Cancerous inhibitor of protein phosphatase 2A contributes to human papillomavirus oncoprotein E7-induced cell proliferation via E2F1. Oncotarget. 2015;6(7):5253–62.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Abolhoda A, Wilson AE, Ross H, Danenberg PV, Burt M, Scotto KW. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin Cancer Res. 1999;5(11):3352–6.PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Juan Liu
    • 2
  • Meng Wang
    • 3
  • Xiaoli Zhang
    • 2
  • Qingwei Wang
    • 3
  • Mei Qi
    • 2
  • Jing Hu
    • 1
  • Zhiqiang Zhou
    • 1
  • Chunyan Zhang
    • 1
  • Weifang Zhang
    • 2
  • Weiming Zhao
    • 2
  • Xiao Wang
    • 1
  1. 1.Department of Pathology, School of MedicineShandong UniversityJinanPeople’s Republic of China
  2. 2.Department of Microbiology and Key Laboratory for Experimental Teratology of Chinese Ministry of Education, School of MedicineShandong UniversityJinanPeople’s Republic of China
  3. 3.Department of Radiation OncologyQi Lu hospital of Shandong UniversityJinanPeople’s Republic of China

Personalised recommendations